News
Attorneys
Practice Areas
AUTM 2025 Annual Meeting
AUTM’s Annual Meeting is the largest gathering of technology transfer professionals. This annual, international meeting is a chance to connect, and gain insights from world-class speakers and panels from more than 90 educational sessions. The 2025 meeting will be held March 2-5, 2025 near Washington, D.C. in the Gaylord National Resort and Convention Center in Maryland. Anne Maxwell, Ph.D., Charlie O'Brien, and Bryan Zerhusen, Ph.D., will attend.
Anne Maxwell is Partner and Chair of the Pharmaceutical Patent Practice. She provides all aspects of patent representation to clients working in chemical and life science research with a particular emphasis on the pharmaceutical and agricultural chemical industries and is trusted counsel to numerous university technology transfer offices. She performs searches, determines patentability and freedom to operate, drafts and prosecutes patent applications, counsels clients in their development of effective patent protection worldwide, and assists clients with licensing and due diligence.
Charlie O'Brien is Partner and Chair of the IP Transactional Practice. He concentrates his transactional practice on the exploitation, transfer and licensing of technology. Charlie has extensive experience in all aspects of complex IP licensing, including the preparation and negotiation of patent license agreements, software license agreements, joint development agreements, trademark license agreements, material transfer agreements, joint marketing and promotion agreements, and the like.
Bryan Zerhusen, Ph.D. is Partner and Chair, Life Sciences Practice. His clients include solo inventors, academic institutions, foreign law firms, venture firms, as well as companies ranging from start-ups to global corporations in the medical biotechnology, agricultural biotechnology, diagnostic, chemical, pharmaceutical, medical device and healthcare sectors. Bryan also has extensive experience negotiating and preparing agreements relevant to the life science industry, including collaborative agreements and IP licensing agreements on behalf of solo inventors, venture firms, start-ups and emerging companies.
